Abstraci
Misoprostol is a synthetic prostaglandin E l analogue (PGEl), originally approved for the prevention and treatment of gastric ulcer. Its effectiveness has been investigated in elective rnedical abortions, labor induction, uterine evacuation following fetal death, postparturn hemorrhage, and ceMcal maturation, particularly in countries where abortion is 1egall.z.
In Brazil, rnisoprostol has become the most popular recourse for inducing abortion, although this practice is illegal, with only nvo exceptions: cases in which the pregnant lvornan's life is at risk, and prcgnancies resulting from rape 3. Use of rnisoprostol by wornen seeking treatrnent at emergency services due to incomplete abortions calls attention to the resulting materna1 health risk Besidcs rnisoprostol, drugs containing esi trogens and progestagens have been associatcd wvith attempted abortions 4,5,617.
Materna1 health risk is not the only problem associated wvith indiscriminate use of abortive substances. According to controlled clinical trials, medical abortions using rnisoprostol can lead to failed abortion in more than 10% of cases, requiring the use of a complernentary abortive method 1.The single use of rnisoprostol is significantly lcss effective than combinations with rnifepristone, methotrexate, or tarnoxifen, and is not recommended in cases of firsttrirnester rnedical abortion 1.8. In conditions -wvhere illegal abortion is commonly performed, andSi40 Paulo (Si40 Paulo) from February 1991 to wvithout adequate care and at lnadequate doses, June 1995. The health services wvere chosen on the use of misoprostol may fail to interrupt the the basis of demand by pregnant wvomen treated pregnancy, thus generating anxiety concerning there and feasibility in the implementation and risk to the fetus 9. Case reports and case-con-followv-up of al1 phases in the Brazilian Study on trol studies suggest that the use of misopros-Gestational Diabetes. tol in unsuccessful abortions can be associated Inclusion criteria data wvere obtained from with congenital anomalies. including cranial the woman's medical chart or prenatal card. For nerve defects 10 and Moebius sequence 11.12. A first appointments, the data could be obtained systematic review of four case-control studies directly from the patient. Women wvith a history on the adverse effects of misoprostol on preg-of diabetes mellitus prior to the pregnancy were nancy outcome showed that prenatal exposure excluded. to misoprostol increases the odds of Moebius Tlie interviewvwas structured to answver quessequence and terminal transverse limb defects, tions relatcd to socio-demographics, in addition as compared to unexposed individuals 13. How-smoking. alcohol, medication, and reproductive ever, the association between misoprostol and history. Variables related to the current pregnanother types of congenital anomalies {vas not ad-cy, delivery, and neonatal health conditions were equately elucidated in this analysis, due to inter-collected from the mother's medical chart. The study heterogeneity. specific use of products to induce menstmation In this context, the objective of the current was investigated wvith the question: "To discover study is to evaluate the association between wltetlieryorc werepregitniit, d i d p u irsesoine kiiid misoprostol and other wvidely used products for ofdrugforyourperiod to come?". inducing menstruation, and congenital anomaData on diagnosis of congenital anomaly lies in fetuses and newvborns. A letter wvith a pre-were collected from the mother's medical chart. liminary analysis of the main findings presented Congenital anomalies wvere classified according in this article \vas published previously by the to the 9th Revisi6n of the International Classificaauthors 14.
. tion of Diseases (ICD-9) 15. The composition of each of the products reported by the wvomen wvas identified ~vith the aid of the Catdlogo Brnsileiro Methods de Especialidades Fnrmacêl~ticas, Diciondrio de Especinlidades Farmncêl~ricns, editions 1984 The current study is a secondaty analysis of the through 1995 16817~l~~~90202122~23,24425252627,anddnig Brazilian Study on Gestational Diabetes, a multi-package inserts. center cohort that investigated diabetes and Data were stored using Epi Info version glucose intolerance in pregnant wvomen in rela-6.04b (Centers for Disease Control and Prevention to prevalence, risk factors, incidence of ob-tion, Atlanta, USA) and analyzed wvith SPSS verstctric and neonatal complications, prognostic sion 13.0 (SPPS Inc., Chicago, USA). A logistic factors, and diagnqstic criteria. The first phase regression model \vas used to estimate the odds pf the stpdy included the enrolment of pregnant ratios (OR) adjusted for'potential confounders wvomen, interviews, anthropmetric measures, reported in the literature. The first phase of the and a glucose tolerance test, when the wvomen model's construction exarnined various riskfacwere in the 21st to 28h wveek of pregnancy. The tors for the target outcorne, testingsocio-demosecond phase involved followv-up of the preg-graphic factors (age, skin color, schooling, study nancy through a patient chart review. The third center. marital status, and pre-gestational body phase consisted of information on delivery and mass index -BMI); reproductive history (previthe newvborn.
ous abortion, planning of the index pregnancy, The study analyzed the data on use of miso-and parity); prenatal care (gestational age at first prostol and other products to induce menstruaprenatal visit, and number of visitsl; gestational tion during the gestational period, recorded complications (gestational diabetes and hyperduring the first phase of the BraziIian Study on tension) and use of substances like tobacco and Gestational Diabetes. The sample consisted of alcohol. Statistically significant variables (dewomen 20 years or older wvho were in the 21st fined as p c 0.25) according to the individual to 28th week of pregnancy, and who consecu-analyses were selccted for the second stage, in tively sought care at prenatal services in health which each variable was tested separately in units under the Unified National Health System the model containing the predictive target vari-(SUS) located in Fortaleza (Ceara State), Manaus able. The variable wvith the largest contribution, (Amazonas), Porto Alegre (Rio Grande do Sul), measured by goodness of fit, wvas added to the Rio de Janeiro (Rio de Janeiro), Salvador (Bahia), model. Next, the model containing the variable Table 1 determined in the previous stage was tested for the remaining variables. This procedure was performed until no more statistically significant contribution to tlie mode1 was observed, accordlng to goodness of fit and the corresponding p > 0.05.
The original study was approved by the institutional revierv boards at each study center. Data from the questionnaires, the object of this secondary study, were treated according to the confidentiality principle. 
Results
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From the initial sample of 5,564 pregnant women followed frornrun-inuntil hospital discharge, the study analyzed 4,856 women (87.3%). 708 tvomen tvere excluded due to lack of information on use of drugs to induce menstruation and maternai characteristics like age, schooling, and skin color, among others. Table 1 shorvs the distribution of the principal socio-demographic characteristics of the women included in the study Ofthepregnant women analyzed, 707 (14.6%) stated having used some product to induce menstruation, ofrvhom243 reported the use of herbal teas (34.4%), 200 reported sex hormones (28.3%), and 120 misoprostol(17%) ( Table 2) .
Sex hormones reported by the wornen included combinations of estrogens and progestagens present in oral contraceptives, injectable medroxyprogesterone, and the association of normethandrone and rnethylestradiol. The teas included various plant species, like senna, "marcela", and quinine.
To investigate the association betïveen use of mlsoprostol, sex hormones, or herbal teas and congenital anomalies, data were analyzed from 4,693 pregnant women, after excluding 163.ïvomen due to lack of information on presence or absence of congenitai anomalies in the newborn. Table 3 shows a positive association for congenital anornaiy tvith misoprostol, ïvith borderline significance (OR = 2.46; 95%CI: 0.98-6.171, and for sex hormones (OR = 2.45; 95%CI: 1.17-5.15). The anomalies occu,ming in women lvho used misoprostolwere: syndactyly, clubfoot, meningomyelocele, microcephaly, and fingernaiI defects. No association was obsemed behveen teas and the target outcome. Table 3 sho~vs the results of logistic regression. After adjusting for confounders, the positive associations shorvn in the crude analysis . remained for misoprostol (OR = 2.64; 95%CI:
1.03-6.75) and sex hormones (OR = 2.24; 95%CI: 1.06-4.741. 'Variation in total numberof pregnant women in the categories was due to missing data for the respeciive variables. ' Anti-inflamrnatoiy analgesics and dwgs whose composition was not identified ('cocktail".
'medicine to start rnenstnial period", and other ternis mentioned by subjects). According to this cohort of pregnant women Importantly, meningomyelocele is a defect that treated at prenatal services in six Brazilian State occurs in the fifth week after the date of the last capitals, fetuses exposed to rnisoprostol show menstrual period, norrnally when the woman a risk of congenital anomaly 2.74 times greater still does not know she is pregnant. Thus, one (95%CI: 1,06-7,05) than that of unexposed fetus-cannot rule out the hypothesis that the anomaly es, as diagnosed at birth. A positive association occurred before the patient tookmisoprostol. wvas also observed behveen use of sex hormones
The principal hormones associated with and congenital anomalies.
congenital anomalies were the combination of An analysis of 4,673 cases of birth defects re-normethandroné and methylestradiol and comcorded in Brazil from 1989 to 1998 showed no dif--pound hormonal contraceptives wvith levonorg-.
ferences in misoprostol exposurc rates betwveen estrel and ethynylestradiol. At the time in wvhich newvborns with al1 types of anomalies (3414,673) the data were collected, the normethandronel as compared to thecontrol group (2314,980), con-rnethylestradiol combination and medroxyprosisting of newvborns wvithout anomalies 28. HOW-gesterone acetate were wvidely used in Brazil as ever, there was a positive association behveen a pregnancy test or in attempts to induce abormisoprostol and vascular disruption defects. tion 32. The followving anomalies were associated Brasil et al. 29 showed a positive association be-wvith the use of hormones in the current analysis: tiveen misoprostol and various types of congeni-polydactyly, wvith orlvithout syndactyly (3 cases), ta1 anomalies in verylow birth weight newvborns, syndactyly (l), congenital scoliosis (l), right chowvith borderline significance, after adjusting for anal atresia (l), ambiguous genitalia (11, and hymaternai age and birth wveight (OR = 2.4; 95%CI: pertrophy of labia minora (1) . Although various 1.0-6.2). In the study, the controls also had birth publications from the 1970s associated the intrawveight < 1,50Og, but wvithout a diagnosis of any gestational use of sex hormones with birth decongenital anomaly.
fects, meta-analyses of cohort and case-control In order to avoid potential biases due to se-studies showed that estrogenlprogestagen comlection of healthy controls, Vargas et al. 30 com-binations were not associatedwvith increased risk pared 93 newborns wvith various vascular dis-of congenital anomalies in general33 or genitoruption anomalies and 279 controls wvith minor urinary malformations in particular 34. or chromosomal anomalies, arnong other birth
The cases of pseudo-hermaphroditism and defects not caused by vascular disruption. Prena-masculi~iation of the genitalia observed in this tal exposure to rnisoprostol \vas identified in 32 analysis may be explained by the use of high doscases (34.4%) and 12 controls (4.3%) (OR= 11.67; es of products containing sex hormones, not as 95%CI: 5.68-23.97).
a contraceptive method or pregnancy test, but In the current study, the observed birth de-to attempt to intermpt pregnancy. Literature fects associated wvith rnisoprostol were classified revieivs suggest that the degree of masculinizaas anomalies of the: nervous system (meningo-tion or abnormal sexual differentiation is dosemyelocele and microcephaly), musculoskeletal dependent 34,35, so that there is no evidence of system (clubfoot and syndactyly), and tegument teratogenic risk associated wvith inadvertent use (fingernail defects). These anomalies may be re-of loi-dose sex hormones during pregnancy36. lated to vascular disruption, resulting from damDespite some case reports on the toxicity of age to or interruption of normal vascular devel-the medicinal plants reported by women in the Cad. Saijde PSblica, Rio de Janeiro, 24(6):1447-1453, jun. 2WB current study to induce menstruation, no association {vas observed behveen the use of herbal teas and congenital anomalies. The \vide variety of teas reported by the wvomen, including some products ~vhose composidon was impossible to verify, and the relatively small number of congenital anomalies, preclude any conclusion on potential teratogenic effects of the medicinal plants used in this study sample.
The current study presents some limitations. The analysis is based on secondary data, jvhich explains the absence of some useful information like the period of gestation in wvhich misoprostol !vas used and the combined use of non-pharmacological abortive methods, which lvould have aliowved a more detailed evaiuation of the teratogenic risk. In relation to the outcome measures, diagnosis of congenital anomalieswas perfomed by the attending neonatal physician, without confirmation by the researchers involved in the current study. Moebius sequence, for example, can go unnoticed in the initiai neonatai evaluation, as can some central nervous system defects, lvhich tend to manifest later (at days or months of life). Therefore, the real association betrveen the products used to induce menstruation and the congenital anomalies may be underestimated in this anaiysis.
MISOPROSTOLAND HORMONES AND RlSK OF CONGENITALANOMAL~ ,451
The available data in the literature on the perinatal effects of misoprostol are mostly from ! cases reports. followved by case-control studies t wvith small samples and major inter-study methodologicai differences, as showvn by a systematic review 13. In addition, the report of exposure to misoprostol before the outcome (childbirth or 
i
The question on the use of misoprostol, hor-! mones, and other abortive products duringpregnancy involves highly complex problems, like non-medical abortion, irrationai dmg use, and the importance of congenital anomalies as a proportionaily increasingcause ofinfant mortality37. In this context, the association benveen the use of misoprostol or sex hormones and congenital anomalies as observcd in the current study contributes to knowledge on the teratogenic poten-:l tial of these products used by Ivomen to induce menstruation, but with abortion as the probable intent. Mcanwhile, the \vide variety of teas reported by pregnant ivomen (forming a broad, heterogeneous group) precludes any conclusion on an association benveen herbal teas and adverse events in the pregnancy outcome in this sample. 
